Michelle Haber

This study identifies venetoclax-alisertib as a promising combination therapy for high-risk neuroblastoma, particularly effective in MYCN-amplified models, with improved survival and reduced toxicity.

The paper identifies FGFR aberrations as actionable targets in pediatric and AYA sarcomas using multi-platform profiling and shows FGFR inhibitors can inhibit tumor growth in PDX models.

This study uses single-cell RNA-sequencing of cerebrospinal fluid to identify circulating tumour cells in children with brain cancer, revealing their dynamics and potential as biomarkers.

The paper identifies JNK-independent drugs that, when combined with standard chemotherapy, improve response in relapsed high-risk neuroblastoma by exploiting differential apoptotic network utilization.

This paper shows RNA-seq can detect most mutations found by WGS in pediatric tumors and provides additional insights into their pathogenicity.

This study identifies ATP13A3 as a polyamine transporter mediating DFMO-induced polyamine uptake in neuroblastoma, highlighting it as a therapeutic target.

This study designs CRISPR-Cas13b crRNAs with single-base precision to silence oncogenic gene fusions, enhancing targeting efficacy and selectivity.

This paper genomically characterizes 261 pediatric cancer patient-derived xenograft models to guide rational clinical trial design and drug development.